Why the study?
Doxorubicin clinical use is limited by cardiotoxicity, and the mechanism underlying the protective effect of caffeic acid phenethyl ester against doxorubicin-induced cardiotoxicity remained to be explored.
Does Caffeic acid phenethyl ester (CAPE) protect against doxorubicin-induced cardiotoxicity in preclinical models?
Population
Mice with doxorubicin-induced cardiotoxicity and in vitro H9c2 and AC16 cells
Comparison
CAPE treatment vs controls in doxorubicin-induced cardiotoxicity models
Design
In vivo and in vitro experimental preclinical study
Authors
Loading...
Hypothesis-generating for CAPE in DIC; leaves open clinical translation pending human trials.
Does Caffeic acid phenethyl ester (CAPE) protect against doxorubicin-induced cardiotoxicity in preclinical models?
CAPE protects against doxorubicin-induced cardiotoxicity by inhibiting ROS-MLKL-mediated cross-talk between oxidative stress and necroptosis in preclinical models.
Jiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: